53 Result(s)
-
Article
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
The topoisomerase I inhibitor topotecan has shown activity in acute myeloid leukemia (AML) and myelodysplastic syndromes. The present study was designed to assess whether topotecan with cytosine arabinoside (a...
-
Article
Phase I study of liposomal daunorubicin in patients with acute leukemia
The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing to...
-
Article
Promising Approaches in Acute Leukemia
In the last few decades, there has been a significant improvement in theprognosis of patients with acute leukemias. Still, the majority ofpatients succumb to these diseases. In recent years there has been a gr...
-
Article
Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia
Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF)is a semisynthetic illudin analog with broad in vitroanti-neoplastic activity. In this leukemia phase I study, weinvestigated the toxicity profile and activity...
-
Article
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
Abstract
-
Article
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
Abstract
-
Article
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Abstract
-
Article
New Strategies in Chronic Myeloid Leukemia
Most patients with chronic myeloid leukemia (CML) achieve clinically relevant hematologic and cytogenetic responses to imatinib. Patients who show resistance to imatinib need new therapeutic options. A range o...
-
Article
The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents
Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced transl...
-
Article
Open AccessIncidence of hip fractures in Salamanca, Spain. Period: 1994–2002
The incidence of hip fractures in Salamanca (Spain) has been lower than in other countries, but has shown a marked increase during the past few decades. The aim of this work is to ascertain the real incidence ...
-
Chapter
New Therapies for Chronic Myeloid Leukemia
Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a nee...
-
Article
Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs
Identify treatment interruptions and non-adherence with imatinib; examine the clinical and patient characteristics related to treatment interruptions and non-adherence; and estimate the association between tre...
-
Article
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
A phase I study was performed to determine the safety and pharmacokinetics of XK469R in patients with refractory acute leukemia. The study aimed to determine the maximum tolerated dose (MTD) and dose limiting ...
-
Article
Treatment selection after imatinib resistance in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a const...
-
Article
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience
Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30% of these patients will relapse, including a small propo...
-
Article
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to mye...
-
Article
Imatinib and beyond—exploring the full potential of targeted therapy for CML
Imatinib is the standard frontline therapy for patients with chronic myeloid leukemia (CML); however, a substantial number require alternative therapy owing to imatinib intolerance or imatinib resistance. Stud...
-
Article
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?
Imatinib mesylate, 400 mg/d, is considered standard therapy for managing patients with chronic myeloid leukemia (CML) in chronic phase, yielding high rates of cytogenetic responses that translate into favorabl...
-
Article
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
Cytogenetic abnormalities in patients with essential thrombocythemia (ET) are infrequent. Their role in survival of patients and disease transformation is not extensively studied. We describe cytogenetic abnor...
-
Article
Tyrosine Kinase Inhibitors: The First Decade
The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting this leukemogenic prot...
